Risperidone News
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug–Drug Interactions and Genetics: Part I
BACKGROUND: Personalized prescription is described even in lay journals, but there has been no attempt to propose personalizing dosing for any specific psychiatric drug.
Acadia Pharma To Present Data From Its Pimavanserin Phase II Schizophrenia Co-therapy Trial
Tuesday morning, biopharmaceutical company Acadia Pharmaceuticals, Inc. said that it would present data from its pimavanserin Phase II schizophrenia co-therapy trial on February 5, 2008.
Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study...
Teva Trying to Assert Its Rights
A reader recently e-mailed me about an interesting citizen petition that Teva (TEVA) filed last August. In the petition, (pdf) Teva requested that the FDA:
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
BACKGROUND: Aggressive challenging behaviour is frequently reported in adults with intellectual disability and it is often treated with antipsychotic drugs. However, no adequate evidence base for this practice exists. We compared...